-
Israel strikes Iran as Tehran rejects US talks overture
-
Mercedes teen ace Antonelli wants more of the same after maiden win
-
Singer Rosalia quits Milan concert with food poisoning
-
Oil climbs and equities sink amid mixed messages on 'talks'
-
'Get out': Verstappen bans reporter from Japan press conference
-
Leaked Nepal report into deadly uprising calls for prosecuting ex-PM
-
Verstappen says last-minute F1 rule tweak will help only 'a tiny bit'
-
Oil rises and equities mixed amid mixed messages on 'talks'
-
EU to vote on Trump tariff deal -- but eyes rest of world
-
Somalia football slowly becomes a women's game
-
Venezuela oil reserves both entice and repel energy giants
-
Hamilton says more committed to F1 than ever at 41
-
China bans runner after mid-marathon splits goes viral
-
Myanmar's rebuild stutters year after deadly quake
-
Murray's 53 points propel Nuggets over Mavs
-
Israel strikes Iran as Trump says Tehran wants deal to end war
-
Wilkinson calls for England to find consistency before World Cup
-
Norris talks up McLaren chances after double China disaster
-
Teen sprint star Gout Gout 'ready to rock and roll' in Melbourne
-
Hezbollah rejects truce talks as Israel presses Lebanon strikes
-
Mideast war fuels disinformation about Taiwan's gas supply
-
Kohli, Suryavanshi to light up IPL as stampede dead remembered
-
Moon race: how China is challenging the US
-
Zimbabwe lithium export ban triggers crackdown, concerns
-
Embiid, George make triumphant NBA returns in Sixers win
-
North Korea's Kim 'warmly' welcomes Belarusian leader
-
Oil edges up and equities mixed amid mixed messages on 'talks'
-
Russian oil arrives as Philippines battles 'energy emergency'
-
G7 meets in France to narrow transatlantic Iran split
-
WTO mulls future of global trade under cloud of Mideast war
-
McKellar tells Waratahs to 'roll sleeves up' against rivals Brumbies
-
Iran says 'no negotiations' as US warns to accept 15-point deal
-
Postecoglou 'not done yet' as he watches Spurs and Forest battle relegation
-
US activists work to connect Iranians via Starlink
-
MLS dreams of global fanbase after World Cup showcase
-
Sabalenka and Rybakina to clash again in Miami semi-final
-
Former Australian Rules player is first to come out as openly gay
-
London plans two-day mega 100,000-runner marathon
-
UN pushes fuel solution for Cuba aid work amid US talks
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 26
-
Guardian Metal Resources PLC Announces Appointment of CFO and Board Changes
-
Connecting Excellence Group PLC Announces Interim Results for the Period Ended 31 Dec 2025
-
Vanta Announces U.S. Ticker Symbol Change to VNTXF
-
Belarus' Lukashenko greeted by North Korean leader in Pyongyang
-
Video shows Chiefs star Mahomes making progress in NFL comeback
-
Bayern beat Man Utd in five-goal women's Champions League thriller
-
Wales would be 'massive asset' to World Cup, says Bellamy
-
NFL champion Seahawks to open season on September 9
-
Silver vows NBA tanking solution before draft, seeks Euroleague partnership
-
Day of reckoning arrives for social media after US court loss
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
T.Sanchez--AT